Effects of Short-Term Treatment
with the α(1)-Blocker Alfuzosin on
Urodynamic Pressure/Flow
Parameters in Patients with Benign
Prostatic Hyperplasia

Martorana, Giuseppe; Giberti, Claudio; Silverio, F. Di; Heland, Magnus von; Rigatti, Patrìzio; Colombo, R.; Casadei, Gianluigi; Pacifico, P.

doi:10.1159/000480880

Cited by 37 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The α 1 ‐adrenoreceptor antagonists doxazosin and alfuzosin are structurally related to each other. Although double‐blind, placebo‐controlled studies have confirmed the efficacy of these two selective α 1 ‐blockers separately [7–12], no comparative studies evaluating these agents have been previously reported. This report presents the results from a study comparing the efficacy and safety of doxazosin with alfuzosin in the treatment of patients with moderate to severe LUTS caused by BPE.…”

Section: Introductionmentioning

confidence: 99%

Comparative efficacy of two α₁‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement

Reijke

Klarskov

2004

BJU International

View full text Add to dashboard Cite

8.8 mg/day. The least squares mean ( SE ) change from baseline in total IPSS was -9.23 (0.6) for doxazosin and -7.45 (0.6) (both P < 0.001) for alfuzosin. The respective mean change from baseline in irritative symptoms was -3.5 (0.2) and -2.8 (0.3) (both P < 0.001). The differences between the treatment groups were statistically significant in favour of doxazosin (total IPSS, P = 0.036; irritative symptoms, P = 0.049). The improvement between groups was also significantly different for postvoid residual urine volume, at -29.19 (8.6) and +9.59 (8.9) mL for doxazosin and alfuzosin, respectively ( P = 0.002). Improvements in mean and maximum urinary flow rates were similar for both treatments, at +1.5 and +1.2, and +2.8 and +2.5 mL/s, respectively. Doxazosin and alfuzosin were both well tolerated, with most all-cause adverse events reported as mild or moderate. CONCLUSIONSThe mean doses of doxazosin and alfuzosin used in this study were not equipotent. Doxazosin 6.1 mg/day produced significantly greater improvements than alfuzosin 8.8 mg/day in total and irritative urinary symptom scores and postvoid residual urine volume in men with moderate to severe LUTS. Changes in maximum and mean flow rates were comparable. Doxazosin and alfuzosin were both well tolerated. KEYWORDSdoxazosin, alfuzosin, benign prostatic enlargement, lower urinary tract symptoms, efficacy OBJECTIVESTo compare doxazosin and alfuzosin in patients with moderate to severe lower urinary tract symptoms (LUTS) suggestive of bladder outlet obstruction. PATIENTS AND METHODSIn all, 210 men with LUTS were randomized to receive doxazosin 1-8 mg once daily or alfuzosin 5-10 mg divided in two or three daily doses in a 14-week, multicentre, double-blind, baseline-controlled, dose-titration study. The International Prostate Symptom Score (IPSS) and maximum urinary flow rate were used to assess the efficacy of the treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative efficacy of two α₁‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement

Reijke

Klarskov

2004

BJU International

View full text Add to dashboard Cite

show abstract

“…A further nine papers were excluded due to the fact that BOOI could not be extrapolated or because of previous therapy with ABs. Finally, 23 studies involving 1044 patients were included in the meta‐analysis (Figure ) . Specifically, the studies evaluating the urodynamic effects of ABs, 5‐ARIs, phytotherapic compounds, and PDE5Is were 18, 3, 2, and 1, respectively.…”

Section: Resultsmentioning

confidence: 99%

Alpha‐1 adrenergic antagonists, 5‐alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta‐analysis of urodynamic studies

Fusco

Creta

Nunzio

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…The prevalence of BPH rises from 138 per 1000 men aged 40 to 49 years to 430 per 1000 men aged 60 to 69 years. 20 By the age of 80 years, around 80% of men are affected, 21 and it is estimated that nearly half of these patients will develop moderate (International Prostate Symptom Score [I-PSS] of [8][9][10][11][12][13][14][15][16][17][18][19] to severe (I-PSS ≥ 20) urinary symptoms that will interfere with normal daily activities and impair quality of life. 22,23 At present, the number of individuals older than age 65 years is increasing faster than any other age group.…”

Section: Pharmacokinetics and Safety Of A Single Oralmentioning

confidence: 99%

“…Both formulations have proven efficacy in several placebo-controlled studies. 1,10,14,15 A new controlled-release formulation of alfuzosin, administered once daily (od) after a meal, has recently been developed to improve patient convenience. This once-daily formulation is bioequivalent to both the 2.5 mg tid and 5 mg bid forms (AUC are similar), and it provides convenience of dosing, as well as sustained clinical efficacy over 24 hours.…”

mentioning

confidence: 99%

Pharmacokinetics and Safety of a Single Oral Dose of Once‐Daily Alfuzosin, 10 mg, in Male Subjects with Mild to Severe Renal Impairment

Marbury

Blum²,

Rauch

et al. 2002

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The effect of renal impairment on the safety and pharmacokinetics of a once-daily formulation of alfuzosin, 10 mg, was evaluated. In an open, single-dose study, 26 volunteers, ages 18 to 65 years, were classified as having normal renal function (n = 8) or mild (n = 6), moderate (n = 6), or severe (n = 6) renal impairment. Mean Cmax values increased by a factor of 1.20, 1.52, and 1.20 in subjects with mild, moderate, or severe renal impairment, respectively, compared with controls. Values for AUC(0-infinity) were 1.46, 1.47, and 1.44, respectively. The t(1/2z) was increased only in the group with severe renal impairment. Emergent vasodilatory adverse events were reported by 4 of 26 subjects. No discontinuations due to adverse events occurred. Laboratory parameters were satisfactory in all groups. In conclusion, once-daily alfuzosin, 10 mg, could be safely administered to patients with impaired renal function, and dosage adjustment does not seem necessary.

show abstract

Effects of Short-Term Treatment with the α(1)-Blocker Alfuzosin on Urodynamic Pressure/Flow Parameters in Patients with Benign Prostatic Hyperplasia

Cited by 37 publications

References 13 publications

Comparative efficacy of two α₁‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement

Comparative efficacy of two α₁‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement

Alpha‐1 adrenergic antagonists, 5‐alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta‐analysis of urodynamic studies

Pharmacokinetics and Safety of a Single Oral Dose of Once‐Daily Alfuzosin, 10 mg, in Male Subjects with Mild to Severe Renal Impairment

Contact Info

Product

Resources

About

Effects of Short-Term Treatment with the α(1)-Blocker Alfuzosin on Urodynamic Pressure/Flow Parameters in Patients with Benign Prostatic Hyperplasia

Cited by 37 publications

References 13 publications

Comparative efficacy of two α1‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement

Comparative efficacy of two α1‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement

Alpha‐1 adrenergic antagonists, 5‐alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta‐analysis of urodynamic studies

Pharmacokinetics and Safety of a Single Oral Dose of Once‐Daily Alfuzosin, 10 mg, in Male Subjects with Mild to Severe Renal Impairment

Contact Info

Product

Resources

About

Comparative efficacy of two α₁‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement

Comparative efficacy of two α₁‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement